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Familial Mediterranean Fever and Hyp e r immuno - 
globulinemia D Syndrome: Two Diseases with Distinct 
Clinical, Serologic, and Genetic Features
AVI LIVNEH, JOOST P.H. DRENTH, INA S. KLASEN, PNINA LANGEVITZ, JACOB GEORGE, DAVID A. SHELTON, 
DEBORAH L. GUMUCIO, ELON PRAS, DANIEL L. KASTNER, MORDECHAI PRAS, and JOS W.M. van der MEER
ABSTRACT\ Objective. To determine whether the 2 periodic febrile syndromes familial Mediterranean fever
(FMF) and hyperimmunoglobulinemia D syndrome (HIDS) are distinct diseases.
Methods. Clinical manifestations of the diseases were analyzed by physicians experienced with 
FMF and HIDS. Serum immunoglobulin (Ig) levels were studied in 70 patients with FMF using 
nephelometry or ELISA and compared with Ig levels in 50 patients with HIDS. Genetic linkage of 
HIDS with the chromosome 16 polymorphic locus RT70, currently used for refined localization of 
the FMF susceptibility gene (MEFV), was studied in 9 HIDS families (18 patients) using polymerase 
chain reaction amplification and gel electrophoresis.
Results. The main clinical features distinguishing FMF from HIDS were lymph adenopathy, skin 
eruption, and symmetrical oligoarthritis in HIDS, and monoarthritis, peritonitis, and pleuritis in 
FMF Increased IgG levels were found in 12 patients with FMF (17%), IgAin 16 (23%), IgM in 9 
(13%), and IgD in 9 (13%), significantly lower than the prevalence reported for HIDS. We found no 
evidence for genetic linkage between HIDS and the chromosome 16 marker RT70.
Conclusion. HIDS and FMF are different entities, clinically, immuno logic ally, and genetically.
(J Rheumatol 1997;24:1558-63)
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Familial Mediterranean fever (FMF) is an autosomal reces­
sive disease characterized by recurrent episodes of febrile 
serositis, mostly peritonitis, arthritis, and pleuritis1. 
Although immunologic, serologic, and metabolic factors 
have been studied2"9, the pathogenesis of FMF is still not 
known. The recent mapping of the FMF susceptibility gene, 
designated MEFV, to chromosome 16p10, permits elucida-
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tion of the molecular lesion underlying the disease by posi­
tional cloning.
Hyperimmunoglobulinemia D syndrome (HIDS) is 
another autosomal recessive periodic febrile syndrome, 
characterized by febrile attacks of abdominal and joint 
pain11. While its resemblance to FMF is striking, there are 
suggestions that it is a clinically, serologically, and geneti­
cally distinct entity11”13. However, more data to support 
HIDS's uniqueness are required, as studies distinguishing 
the 2 diseases are limited and based on a small population of 
patients with FMFU. Moreover, progressive narrowing of 
the FMF candidate interval permits reexamination of genet­
ic linkage data on HIDS families. An earlier study12 used 
haplotype analysis with 4 markers from MEFV region of 
chromosome 16p, but the closest marker on the centromeric 
side of MEFV was roughly 10 cM from the gene. We took 
advantage o f a newly identified marker about 1 cM cen­
tromeric to MEFV to perform linkage studies in HIDS fam­
ilies. In addition, we established a collaborative study 
among our centers to compare the clinical and immunologi­
cal features of FMF and HIDS.
MATERIALS AND METHODS
Comparative analysis o f clinical manifestations. Representatives of the 
FMF clinic of Sheba Medical Center and the HIDS clinic at the University 
Hospital of Nijmegen and the HIDS study group who personally attend 
patients with the diseases met at Nijmegen to study the manifestations o f
1
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the 2 diseases for similarities and differences by reviewing and discussing 
the clinical presentation of the diseases. The analysis was based on experi­
ence with 50 patients with HIDS treated by physicians of the hyper-IgD 
study group for the last 15 years, and about 4000 patients with FMF fol­
lowed over the last 40 years as part of an ongoing study in the FMF clinic. 
Clinical features of these patients have been reported1,11,14’15 and recently 
updated13,16.
Determination and comparative analysis of immunoglobulin levels. 
Seventy consecutive patients with FMF, attending the FMF clinic for rou­
tine followup examination, donated 10 ml blood. All were following a con­
tinuous colchicine regimen. Before starting colchicine all had clinical man­
ifestations agreeing with the criteria for FM F1,17. At the time of blood dona­
tion, they were free of attacks. No patient had, in addition to FMF, a rec­
ognized acute or chronic allergic, inflammatory, or infectious condition 
leading to hyperglobulinemia. After clot formation, the serum was separat­
ed and kept at ~20°C until studied.
IgD level was studied by ELISA as described1 Briefly, microtiter 
plates were coated with rabbit antihuman IgD antibody, and sera and stan­
dard solutions with known concentrations of IgD as reference were added. 
The presence of IgD was detected by addition of monoclonal IgG antihu­
man IgD followed by peroxidase conjugated, antimouse IgG and substrate. 
The absorbency was read using an ELISA reader and the level of IgD in 
sera was determined with reference to the standard solutions. Levels of the 
IgG, IgM, and IgA were studied using nephelometry (Cobas Fara, Roche 
Diagnostics, Basel, Switzerland). The immunoglobulin levels in 70 FMF 
and 50 HIDS sera were compared. Ig levels in HIDS sera were determined 
previously by the same laboratory, personnel, and methodology as in the 
current study and were reported as part of a large clinical and laboratory 
study of these patients13.
Determination of the linkage between HIDS and RT70. DNA samples were 
obtained from members of 9 HIDS families, consisting of IS patients and 
26 first degree relatives. Their pedigrees and genomic DNA preparation 
have been reported12. The diagnosis of HIDS was made according to pub­
lished criteria12. These families were genotyped for a newly described 
tetranucleotide-repeat marker derived from cosmid RT70, which is located 
within 1 cM of MEFV on chromosome 16p. Five alleles of this marker 
were identified in the general population19.
RT70 polymerase chain reaction (PCR) primers were synthesized as 
follows: 5'-TCACTCTAGCTTGGGTGAAGG-3' and S'-CCTCTCCA- 
GAGGACAACTGG-3'. The PCR reactions were carried out in a volume 
o f 10 jliI. The reaction mixture consisted of the pair of primers (0.1 pi of 150 
ng/pl each), [32P] labeled primer [0.05 pi from a 15 pi reaction mix con­
taining 187.5 ng 5' primer, 7.5 pi gamma-[32P]-ATP (DuPont, Boston, MA, 
USA; 10 mCi/ml), 1.5 pi T4-polynucleotide kinase (Promega, Madison, 
W I5 USA; 10 U/pl), 10 x buffer and H ,0], genomic DNA (1-2 pi contain- 
ing 25-50 ng), deoxynucleosides triphosphate (GeneAmp dNTPs, Perkin 
Elmer, Branchburg, NJ, USA; 2 pi of a mixture containing 2 pg/ml of each 
o f  the 4 nucleosides), Taq polymerase (0.24 pi of 10 U/pl), 10 x buffer and 
H 20. The PCR program consisted of 30 cycles of 1 min denaturing at 94°C, 
1 min annealing at 55°C, and 1 min extension at 72°C. The reaction was 
stopped with 7 pi loading/stop buffer (formamide, 0.1% xylene cyanol,
0 . \%  bromophenol blue, and 2% 0.5 M EDTA).
Electrophoresis of the PCR products was carried out in acrylamide 
sequencing gels at 1800 V for 3 h. The gel was dried and exposed to film, 
Lod scores defined as logarithm to the base 10 of the ratio of odds in favor 
o f linkage to the odds against linkage between RT70 and HIDS were cal­
culated using the LINKAGE programs, assuming a recessive model of 
HIDS inheritance and a gene frequency of 0.001.
Statistical analysis. Statistical analysis was performed using the chi- 
squared method or Student’s t test, indicated in Results.
of FMF and HIDS is shown in Table 1. The 2 diseases 
appear to be distinct in most aspects, including the duration 
of the attack, the temperature curve, the organs involved and 
the nature of the involvement, the response to treatment, and 
the prognosis. A typical attack of FMF lasts 2 -4  days and is 
characterized by a temperature curve with a fast rise, plateau 
and abrupt fall, peritonitis, pleuritis or monoarthritis, possi­
bly erysipelas-like eruption, and virtually no other dermal 
manifestations or lymphadenopathy (rarely, if ever, in chil­
dren), On the other hand attacks of HIDS are marked by 
longer duration (around a week), gradual defervescence 
(lysis), common occurrence of lymphadenopathy and rash, 
and abdominal pain, which very infrequently develops into 
acute abdomen and symmetrical oligoarthritis or arthralgia. 
Amyloidosis, a life threatening manifestation of FMF, has 
not been noted in HIDS, and colchicine, while very effective 
in FMF, is less effective in HIDS. Additional dissimilarities 
exist, as outlined in Table 1,
Serological analysis. Results of Ig analysis in patients with 
FMF are presented in Tables 2-4. As shown in Tables 2 and
3, abnormally elevated levels of Ig of at least one iso type 
were noted in 34 of 70 patients (49%). Sixteen patients 
(23% of all patients and 47% of patients with increased Ig 
levels) had elevated IgA. Elevated IgM levels were noted in
9 patients (13%), IgG in 12 (17%), and IgD in 9 (13%). In
10 patients, the increased IgA level was associated with a 
concomitant rise of IgG (5 patients), IgD (4 patients), or IgD 
plus IgM (one patient). As a group, however, patients with 
FMF exhibited normal Ig levels between the attacks (Table
4, mean values in FMF).
All 9 patients with FMF (4 men and 5 women) who dis­
played elevated levels of IgD appeared to have classic FMF 
with attacks of peritonitis (9 patients), monoarthritis (7 
patients), and pleuritis (3 patients), and had none of the spe­
cific HIDS clinical features delineated in the previous sec­
tion. All were colchicine responsive and did not have skin 
manifestations or lymphadenopathy. Compared to patients 
with HIDS, patients with FMF had significantly lower rates 
of elevated individual Ig levels (Table 3), and significantly 
lower mean IgA and IgD levels (Table 4). Therefore, in 
addition to differences in IgD, the prevalence of elevated Ig 
levels and mean IgA levels also differentiate the disease.
Molecular analysis. A panel of 9 HIDS families was geno­
typed for the RT70 marker, which is about 1 cM centromeric 
to the FMF susceptibility gene on chromosome 16p. Lod 
scores between HIDS and RT70 are shown in Table 5. Total 
lod scores of < - 2  were obtained up to recombination fre­
quency of 0.03, excluding HIDS from the interval within 3 
cM of RT70. Moreover, haplotype analysis, using RT70 typ­
ings in conjunction with 4 other markers12, also rules out the 
placement of HIDS in the MEFV region of chromosome 16.
RESULTS
Clinical analysis. The comparison of clinical manifestations
DISCUSSION
Although FMF and HIDS share certain features, we
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Table I. FMF and HIDS are clinically distinct.
Manifestation FMF HIDS
Age of onset Usually before age 20 Childhood (70% before
Duration of 1-4 days
1 st year of life) 
3-7  days
attack
Fever Begins and ends abruptly. Sudden rise. Gradual
The temperature curve is of decrease. Chills are common
Abdominal
continuous type. Chills are common 
Occur in most patients. Occurs in most patients;
attacks Diffuse, or less frequently usually pain alone.
localized. Peritoneal Acute abdomen (in
irritation is the rule. < 10%). Diarrhea
Diarrhea is not common (5%) very common (80%)
Joint attacks Presents as monoarthritis Presents as symmetric
of the large joints of oligoarthritis of
lower extremities (75%). large joints of
Poly arthralgia may lower extremities.
occasionally accompany Arthralgia is very
febrile attacks elsewhere. frequent. No chronic
Chronic joints and joint disease found
Thoracic
spondyloarthropathy are rare 
(< 5% and < 1%, respectively) 
Pleuritis is common (25%), Not found
attacks unilateral. Pericarditis is
Rash
rare (< 1%)
Rare (< 5%). Only Very common (90%).
erysipeloid. Those affected Types of rash: macular,
experience only rare maculopapular, purpura.
episodes during lifetime Pathology: vasculitis
“Orchitis” Rare (< 5%), Unilateral, Not found
Muscle pain
Only in childhood and adolescence. Rare 
episodes during lifetime 
Short or prolonged episodes Rare
Lymphadenopathy
of febrile myalgia are uncommon. Afebrile 
muscle pain of lower extremities, usually 
provoked by exertion, is common (30%) 
Questionable in early Generalized and
childhood cervical. Very common (> 90%)
Splenomegaly In about 30% of patients In about 50% of patients
Amyloidosis Develops in many untreated patients Not found
Vasculitis Hypersensitivity, GN, Skin eruption
Genetic origins,
PAN are more common compared to population 
not affected by FMF 
Autosomal recessive. The Autosomal recessive.
populations susceptibility gene is Chromosomal location is
mapped to chromosome 16p. not known. Occurs in
Sephardi Jews, Armenians, Arabs, and Turks Western Europeans
WBC in attack Increased Increased
ESR in attack Increased Increased
Hematuria Common (5%), Present in 20%
Synovial fluid Turbid, inflammatory; Turbid, inflammatory
white cell count > 20 ,000 /jal 
Colchicine treatment Prevents attacks and amyloidosis Usually not effective
WBC: white blood cells; ESR: erythrocyte sedimentation rate; GN: glomerulonephritis; PAN: polyarteritis 
nodosa.
observed that the 2 diseases differ in their clinical manifes­
tations, serum Ig concentrations, and genetics. Lympha- 
denopathy, certain types of rash, and symmetric oligoarthri­
tis are exclusively found in HIDS, while peritonitis,
monoarthritis, and pleuritis are typical to FMF (Table I). 
Increased levels of IgG, IgM, IgA, and IgD have a much 
lower prevalence in FMF compared with prevalence report­
ed in HIDS (Tables 2, 3, 4). Finally, molecular analysis,
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Table 2, Patients with FMF with elevated immunoglobulin levels*.
Patient
IgG
(6.5-15.2
g/1)
Immunoglobuliri Levels 
IgA IgM 
(1.1-3.75 (0.5-2 
g/1) g/1)
IgD
(S 100 
U/ml
3 20.96 1.23 2.0 20
6 14.18 2.63 3.21 < 5
7 12.47 5.92 2.0 57
8 14 6.36 1.46 80
9 16.96 1.74 2.16 51
11 9.06 6.64 1.48 182
13 9.86 2.75 2.12 28
J4 15.54 1.89 0.94 54
15 29.22 5.96 1.91 17
16 13.87 2.42 2.0 696
18 13.25 2.42 2.26 60
19 11.65 6.24 1.07 17
21 12.08 1.77 2.5 58
23 15.5 3.68 1.58 38
27 15.08 8.53 0.76 60
29 16.2 4.14 1.98 3
35 15.08 5.99 1.66 174
36 11.1 1.28 2.44 19
37 16.56 1.68 0.61 19
38 14.4 4.79 1.92 225
41 8.6 7.1 1.42 226
43 15,33 3.34 0.98
i
59
48 13,29 4.55 3.63 146
49 10.32 3.92 0,66 10
55 12.15 6.1 2.0 52
57 18.2 2.99 1.93 45
58 16.14 6.71 0.48 44
60 13.3 3.79 0.8 312
61 12.3 3.67 0.57 190
62 15.20 3 2.8 148
64 9,5 2.89 3.51 64
65 16.28 8.86 0.86 73
67 15.86 4,06 1.98 4
70 15.19 3.70 1.98 49
*Ig levels were determined in 70 patients by nephelometry (IgG, A, M) and ELISA (IgD). Data are from patients 
with increased titers in at least one type of Ig (shown in boldface type).
Table 3. Prevalence of elevated immunoglobulins in FMF (70 patients) and 
H1DS (50 patients). Immunoglobulins were determined using nephelome- 
try (IgG, IgA, IgM) or ELISA (IgD). Results for patients with FMF are 
shown in Table 2; for HIDS in reference13.
Immunoglobulin No. (%) of Patients p*
FMF HIDS
IgA 16(23) 42 (82) < 0.001
IgG 12 (17) 19 (38) < 0.02
IgM 9(13) 17(34) < 0.01
IgD 9(13) 50 (100) < 0.001
Any lg 34 (49) 50 (100) < 0.001
^Chi-squared test.
Table 4 . Mean immunoglobulin levels in FMF (70 patients) and HIDS (50 
patients). Immunoglobulins were determined using nephelometry (IgG, 
IgA, IgM) or ELISA (IgD). Mean lg levels were computed based on Ig 
determination in sera of 70 patients with FMF (Table 2) and from refer­
ence1-1 (50 patients with HIDS).
Immunoglobulin Normal Mean Ig level p*
(g/1) FMF HIDS
IgA 1.1-3.75 3.12 5.54 < 0.001
IgG 6.50-15.20 12,76 13.5 NS
IgM 0.50-2.00 1.47 1.42 NS
IgD ^  100 U/ml 57.22 1158 < 0.001
*SLudent’s t test. NS: not significant.
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Table 5. Linkage between RT70 and HIDS.
Recombination Fraction
0.00 0.01 0.02 0.03 0.04 0.05 0.06
Lod score* -3.85 -2.72 -2.08 -1.65 -1.33 -1.08
*Lod scores of 9 families with one or more progeny with HIDS. Lod scores 
were computed using LINKAGE programs.
using the RT70 marker, confirmed that the HIDS locus is not 
linked to the FMF susceptibility gene on chromosome 16p 
(Table 5).
FMF and HIDS differ clinically in almost every aspect 
studied (Table 1). However, as some overlap does occur, 
recurrent painful febrile attacks may still constitute a diag­
nostic challenge. The clue for correct diagnosis is the pres­
ence of the pathognomonic manifestations outlined above. 
In addition, the origin of the patient is also helpful, as 
patients with HIDS and FMF stem from different popula­
tions (Table 1). Despite serologic characterization of HIDS 
and significant advancement toward the detection of MEFV, 
the diagnosis of the 2 conditions currently still relies on clin­
ical evidence.
Genetic evidence also strongly supports the view that 
FMF and HIDS are distinct entities. That these diseases are 
common in different populations suggested a different 
genetic basis, although there remained the possibility that 
the 2 disorders could be allelic mutations at the same locus. 
However, our present data, coupled with the previous study 
from Drenth, et a l]1, indicates that the HIDS susceptibility 
gene is not linked to the MEFV region of chromosome 16. 
The chromosomal location of the HIDS susceptibility locus 
remains unknown.
Studies focusing on Ig of various isotypes in FMF are 
scarce and report conflicting results. One study showed ele­
vation of IgG, IgM, and IgA during attacks and remissions 
in untreated patients and in patients taking colchicine20. A 
study performed before the era of colchicine use found that 
only the IgG and IgM levels were invariably increased; the 
IgA levels were constantly low (reviewed in 20). A third 
study showed normal IgG, IgM, and IgA in colchicine treat­
ed patients with FMF21. Our results agree with the latter, 
showing normal mean Ig levels in patients with FMF (Table 
4), but also show that about half the patients may display an 
elevated level of Ig of one or more isotypes (Table 3). 
Differences with other studies may stem from variance in 
methodology. Our use of modern automated techniques of 
immunoglobulin determination, combined with our com­
mon experience of normal Ig levels obtained on multiple 
occasions, supports our results.
Our findings have an important consequence: while vir­
tually all patients with HIDS display high concentrations of 
IgDil>13, the opposite is not true; the finding of elevated lev­
els of IgD in a patient with periodic fever is not necessarily 
diagnostic of HIDS. About 13% of our patients with FMF
bad elevated IgD titers, half of them with levels higher than 
twice the normal upper limit (> 200 U/ml, Table 2). The rea­
son for increased IgD in 13% of patients with FMF is not 
clear. None of these patients with FMF had specific mani­
festations of HIDS. In the normal population IgD has a tri- 
modal distribution pattern with a 95% confidence interval 
from 0.19 to 156 U/ml22. It is possible that the high IgD 
values in some patients with FMF reflect the high end of the 
normal distribution.
The finding that IgA levels are elevated in a considerable 
number of patients with FMF is novel and interesting: FMF 
has been associated with increased prevalence of Henoch- 
Schonlein purpura and IgA nephropathy23,24, conditions 
associated with deposition of IgA in the affected tissues24,25, 
FMF is also associated with increased prevalence of 
spondyloarthropathy26, in which raised IgA was found to 
correlate with disease activity and was linked to bacterial 
infection of the gut27. The role of increased IgA level in 
FMF and its association with certain immunologic and 
rheumatologic manifestations of the disease is intriguing 
and is currently being investigated.
The results of the clinical, serological, and genetic analy­
sis in this study suggest that FMF and HIDS are 2 separate 
diseases, differing in their molecular basis, pathogenesis, 
clinical expression, response to treatment, and prognosis. 
How these 2 different entities share common features, such 
as an episodic nature and certain system and organ involve­
ment, remains to be elucidated.
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